Related Experiment Videos
Gene therapy for rheumatoid arthritis
E Gouze1, S C Ghivizzani, G D Palmer
1Center for Molecular Orthopaedics, Harvard Medical School, Boston, MA 02115, USA.
Expert Opinion on Biological Therapy
|December 1, 2001
Summary
Gene therapy offers a promising new treatment for rheumatoid arthritis (RA), a chronic joint disease. Early clinical trials show it is safe and feasible, with further studies planned to assess its effectiveness in patients.
Area of Science:
- Rheumatology
- Gene Therapy
- Immunology
Background:
- Rheumatoid arthritis (RA) is a prevalent, disabling autoimmune disease impacting joints.
- Current treatments improve management but do not offer a cure, necessitating novel therapeutic strategies.
- Long-term protein-based therapies are challenging due to the chronic nature of RA.
Purpose of the Study:
- To explore gene therapy as a potential long-term solution for rheumatoid arthritis.
- To evaluate the feasibility, efficacy, and safety of gene transfer for arthritis treatment.
- To investigate the 'contralateral effect' and its implications for cell trafficking and antigen-presenting cells (APC).
Main Methods:
- Experimental studies in animal models of arthritis.
- Gene transfer to synovial lining cells and systemic gene delivery.
- Phase I clinical trials for ex vivo gene transfer to human synovial lining.
Main Results:
- Gene therapy demonstrated feasibility, efficacy, and safety in animal models.
- Successful completion of a Phase I clinical trial for ex vivo gene transfer.
- Ongoing Phase I trials and planning for a Phase II study in early-stage RA patients.
Conclusions:
- Gene therapy presents a viable and safe approach for treating rheumatoid arthritis.
- The 'contralateral effect' opens new avenues for understanding disease mechanisms and treatment.
- Clinical trials are progressing, indicating a strong potential for gene therapy in RA management.